Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P57105
UPID:
SYJ2B_HUMAN
Alternative names:
Mitochondrial outer membrane protein 25
Alternative UPACC:
P57105; Q49SH3; Q96IA4
Background:
Synaptojanin-2-binding protein, also known as Mitochondrial outer membrane protein 25, plays a crucial role in cellular processes by regulating the endocytosis of activin type 2 receptor kinases. This regulation occurs through the Ral/RALBP1-dependent pathway, highlighting its importance in cellular signaling and membrane trafficking.
Therapeutic significance:
Understanding the role of Synaptojanin-2-binding protein could open doors to potential therapeutic strategies. Its involvement in the suppression of activin-induced signal transduction suggests a pivotal role in cellular communication, which could be leveraged in drug discovery efforts to target diseases with dysregulated activin signaling.